Home Healthcare Medical Devices Deep Brain Stimulation Devices Market

Deep Brain Stimulation Devices Market Size, Share & Trends Analysis Report By Applications (Parkinsons Disease, Epilepsy, Dystonia, Essential Tremor, Obsessive-compulsive disorder, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Neurological Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:

Deep Brain Stimulation Devices Market Size

The global deep brain stimulation devices market size was valued at USD 1.39 billion in 2025 and is projected to grow from USD 1.53 billion in 2026 to USD 3.20 billion by 2034, registering a CAGR of 9.72% during the forecast period from 2026 to 2034. North America dominated the deep brain stimulation devices market with a market share of 42.3% in 2025.

Factors such as the increasing prevalence of neurological disorders and surge in neurological R&D significantly drive the deep brain stimulation devices market demand by 2031.

Deep Brain Stimulation (DBS) devices are medical implants used in neurology to treat certain neurological disorders, particularly movement disorders such as Parkinson's disease, essential tremor, and dystonia. These devices deliver electrical impulses to specific brain areas to modulate abnormal neuronal activity and alleviate symptoms. A typical DBS system consists of three main components: the implanted pulse generator (IPG), the lead, and the extension. The IPG is a small device related to a pacemaker that generates and delivers electrical stimulation.

The lead is implanted in the targeted brain region with multiple electrodes and carries the electrical impulses. The extension connects the IPG to the lead, enabling communication and power supply. Deep brain stimulation devices are crucial in managing movement disorders, providing patients with a viable therapeutic option to alleviate symptoms and improve their daily functioning.

Top 3 Key Highlights

  • Parkinson’s disease dominates the application segment.
  • Hospitals dominate the end-user segment.
  • North America is the highest shareholder in the global market.
Deep Brain Stimulation Devices Market Size

Download a Free Sample To learn more about this report.

Application Insights

The global market is bifurcated into Parkinson’s disease, epilepsy, dystonia, essential tremor, obsessive-compulsive disorder, and others. The Parkinson's disease segment dominates the global market and is expected to exhibit a CAGR of 16.9% over the forecast period. Parkinson's disease is a progressive and chronic nervous system disorder that affects movements and causes the patient to lose control over some bodily functions. Since Parkinson's disease cannot be cured, medications can help control and relieve the symptoms, allowing numerous opportunities for deep brain stimulation to treat PD. Deep brain stimulation devices are usually preferred for patients suffering from PD that relieve symptoms such as tremors, walking difficulties, and balancing issues. Thus, the lower availability of treatment options and the growing patient pool associated with PD are the key drivers of the market for Parkinson's disease.

Additionally, the growing patient pool associated with Parkinson's disease contributes to the deep brain stimulation devices market growth. The prevalence of Parkinson's disease is increasing globally, primarily due to aging populations and improved diagnosis rates. As more individuals are diagnosed with Parkinson's, the demand for effective treatment options like deep brain stimulation is rising.

Deep Brain Stimulation Devices Market Size By Segments

Request Customizationto receive a tailored report.

End-User Insights

The global market is bifurcated into hospitals, ambulatory surgical centers, neurological clinics, and others. The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 17.1% over the forecast period. The hospital segment of the market holds the largest market share due to several factors. Firstly, brain monitoring is a complex process that requires advanced and expensive devices and equipment. These resources are primarily available in hospitals with the infrastructure and resources to support the installation and maintenance of such equipment. Hospitals have the necessary expertise and personnel to perform brain monitoring procedures and handle the associated complexities. Secondly, brain stimulation devices, which are used in conjunction with brain monitoring, also impose a significant financial burden in terms of maintenance expenses on healthcare facilities. Hospitals, being larger and better funded than small clinics and other healthcare settings, are better positioned to bear these costs.

Furthermore, brain monitoring is a multifaceted process that necessitates using sophisticated and costly devices and equipment, typically found in hospital settings. Further, brain stimulation devices place a significant financial burden on healthcare facilities regarding maintenance expenses. Among various end-users, hospitals are better equipped to handle these costs. Moreover, hospitals handle a larger influx of patients compared to smaller clinics and other end users. As a result, brain stimulation devices are predominantly utilized in hospitals, thus accounting for the largest market share.

Deep Brain Stimulation Devices Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global market shareholder and is estimated to exhibit a CAGR of 13.91% over the forecast period. North America constitutes three major countries: the U.S., Canada, and Mexico. U.S. market accounts for the major share of the total market, owing to the increase in the prevalence of various neurological diseases such as Parkinson's disease, depression, and epilepsy. For example, as per the National Institute of Mental Health "Major Depression," 2017, depression affects around 17.3 million adults in America, around 7.1% of the U.S. population annually. In addition, there is increased awareness regarding using deep brain stimulators to treat neurological disorders. Private and government organizations have undertaken various initiatives to raise awareness about chronic pain management and neurological disorders in the region. The desire to increase life quality is high in the U.S., which leads to increased acceptance of deep brain stimulators for pain management and treatment of depression.

Furthermore, technological advancements in deep brain stimulator devices have fueled the growth of the region's market. The elements, including rising rates of neurological conditions, growth in the geriatric population, and recent approvals of deep brain stimulators by Health Canada, are expected to drive the market growth. Deep brain stimulation equipment sales are anticipated to rise in Mexico due to increased healthcare expenditure and growth in awareness of deep brain stimulators.

North America Deep Brain Stimulation Devices Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Deep Brain Stimulation Devices Market Trends

Europe is estimated to exhibit a CAGR of 16.5% over the forecast period. European market is studied concerning five major countries: Germany, France, the U.K., Italy, Spain, and the rest of Europe. Europe occupies the second highest market share in the global market, after North America. Germany holds the major market share in Europe's market, followed by France, the U.K., Italy, and others. The deep brain stimulation devices market in Germany has witnessed steady growth due to factors such as the rise in the incidence of neurological disorders in the region.

In addition, Germany has the highest prevalence of Parkinson's disease in Europe, according to the Competence Network on Parkinson's Disease, a German national network supported by the Federal Ministry of Education and Research. Moreover, per the European Brain Council (EBC) data, 1.2 million people in Europe have Parkinson's disease. Germany accounted for 260,000, Italy accounted for 200,000, Spain accounted for 150,000, the U.K. accounted for 120,000, and France accounted for 117,000. Deep brain stimulation devices are ideal for managing the symptoms associated with neurological disorders; hence, there is lucrative scope for market players in Europe.

Asia Pacific Deep Brain Stimulation Devices Market Trends

The Asia-Pacific region, consisting of Australia, Japan, India, China, and the rest of Asia-Pacific, provides attractive opportunities for players in the market, with expectations of being the fastest-growing market. Market growth is driven by government and private initiatives to increase mental health awareness and the rising incidence of neurological disorders. China holds the largest share in the region, followed by Japan. In addition, India is anticipated to experience significant growth due to increased awareness of mental disorders and higher healthcare spending.

In LAMEA, the rise in incidences of neurological disorders coupled with the rapidly growing senior population drives the rise of the market. In addition, growing research and development activities to treat neurological disorders are expected to strengthen the deep brain stimulation devices market growth. Latin America has a high prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, and epilepsy. Pain management offers a huge market for deep brain stimulation devices. However, there are unmet requirements in this region's due to the countries' lack of efficient treatment systems.

List of Key and Emerging Players in Deep Brain Stimulation Devices Market

Abbott Laboratories
Aleva Neurotherapeutics SA
Boston Scientific Corporation
Medtronic plc
Neuropace Inc.
Nevro Corporation
Neuronetics Inc.
Functional Neuromodulation Ltd
Beijing Pins Medical Co., Ltd.

Key Industry Developments

May 2026
Medtronic expanded its deep brain stimulation portfolio with next-generation adaptive DBS technologies featuring AI-enabled programming and personalized stimulation to improve outcomes for patients with movement disorders.
March 2026
Abbott introduced advanced deep brain stimulation systems with enhanced directional leads, expanded MRI compatibility, and improved clinician programming tools for neurological disorder management.
October 2025
Boston Scientific expanded its Vercise™ DBS portfolio with upgraded software and remote programming capabilities, enabling more personalized therapy for patients with Parkinson’s disease and essential tremor.
June 2025
NeuroPace advanced its neuromodulation portfolio by expanding clinical research into next-generation brain stimulation technologies for the treatment of epilepsy and other neurological disorders.

Report Scope

Segmentation

By Applications 6
  • Parkinsons Disease
  • Epilepsy
  • Dystonia
  • Essential Tremor
  • Obsessive-compulsive disorder
  • Others
By End-User 4
  • Hospitals
  • Ambulatory Surgical Centers
  • Neurological Clinics
  • Others

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Abbott Laboratories · Aleva Neurotherapeutics SA · Boston Scientific Corporation · Medtronic plc · Neuropace Inc.
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The deep brain stimulation devices market size is valued at USD 1.53 Billion in 2026 and is projected to reach USD 3.20 Billion by 2034, at a CAGR of 9.72% during the forecast period 2026-2034.

North America dominated the market with a share of 42.3% in 2025.

The leading players in this market are Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corporation, Medtronic plc, Neuropace Inc..

The deep brain stimulation devices market is projected to grow at a CAGR of 9.72% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: